Last Updated on June 28, 2025 by The Health Master
CDSCO approval
Biocon secures Central Drugs Standard Control Organisation approval (CDSCO approval), which allows the company’s generic diabetes drug Liraglutide to serve the unmet therapeutic needs of millions of Type 2 Diabetes Mellitus patients in India and worldwide.
Step Against Diabetes
This CDSCO approval is more than just another launch—it’s a step in the right direction against the growing incidence of diabetes within India.
The CDSCO approval is for both drug substance Liraglutide developed by Biocon and the drug product Liraglutide (6 mg/ml solution for injection in pre-filled pen and cartridge) developed by Biocon Pharma, Biocon’s subsidiary.
This means that there’s vertical integration for manufacturing and quality, which is essential for the Indian marketplace looking for a reliable and trustworthy generic formulation.
Liraglutide
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
It is the generic version of Victoza.
Liraglutide is indicated for the treatment of adults, adolescents, and children aged 10 years and above with inadequately controlled Type 2 Diabetes Mellitus. Liraglutide is indicated as an adjunct to diet and exercise to improve glycemic control in these patients.
Diabetes in India
India has the highest incidence of diabetes worldwide, with conservative estimates of over 77 million Indians suffering from diabetes—not to mention a projected rise in the future.
Therefore, the market need is substantial to treat incompletely controlled diabetics with innovative yet affordable options.
Additionally, providing a more affordable option not only serves the patient but also plays into the health economics of the Indian health system.
Q. What is Liraglutide ?
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is the generic version of Victoza. Liraglutide is indicated for the treatment of adults, adolescents, and children aged 10 years and above with inadequately controlled Type 2 Diabetes Mellitus.
Q. How does Liraglutide work for Type 2 Diabetes?
Liraglutide works by mimicking the action of a natural hormone in the body that helps regulate blood sugar levels. It stimulates insulin release when blood sugar is high, reduces glucagon secretion (a hormone that raises blood sugar), and slows down gastric emptying, which contributes to a feeling of fullness and can aid in weight management.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
Disclaimer: The information we have provided is for general knowledge and for informational purpose only and it cannot be treated as medical advice. Always consult your doctor for any health issues and / or for the treatment of the same. The Health Master does not claim responsibility for this information.
Online Registration of Cosmetics in India: CDSCO
CDSCO approval granted for Durvalumab for Limited-Stage SCLC in India
CDSCO Approval: For Vedolizumab Biosimilar Clinical Trial
CDSCO approval granted for Eculizumab for rare disease
CDSCO: Sub-Zonal Office established in Bhubaneswar
CDSCO: 14 vacancies for Drug Controller Positions at senior level
NPPA fixed retail price of 41 formulations: June 2025
9.72 kg Methamphetamine Tablets seized, one arrested
USFDA inspection: At Alembic Pharma with 4 observations: Panelav
Portal for Schedule H Drugs Tracking to be launched soon
Key Amendments to the Drugs Rules, 1945: Draft Notification
Veterinary Drug Bust: ₹3 Lakh Illicit Stock Seized
CDSCO: New Labeling Guidelines for Imported drugs
CDSCO Guidelines: Safe Disposal of Expired and Unused Drugs
India to Ban 34 Antimicrobials for animal use
USFDA approval granted for Amlodipine & Atorvastatin Tablets USP
